Intelligence Feed event · Policy · 2026-10-14

    Rhythm Pharmaceuticals launches IMCIVREE in Japan following NHI price listing

    Question

    Rhythm Pharmaceuticals launches IMCIVREE in Japan following NHI price listing

    Direct answer

    Rhythm Pharmaceuticals commenced commercial distribution of IMCIVREE (setmelanotide) in Japan following formal Ministry of Health, Labour and Welfare (MHLW) regulatory clearance. Inclusion on Japan's National Health Insurance price list ensures national reimbursement coverage, establishing the first available therapeutic option for patients with acquired hypothalamic obesity in Japan.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-14
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Rhythm Pharmaceuticals launches IMCIVREE in Japan following NHI price listing”, revision 1, evidence through 2026-10-14. https://marketontology.com/market-events/2026-10-14/rhythm-pharmaceuticals-launches-imcivree-in-japan-following-nhi-price-listing-a67ab9

    POLICY
    Rhythm Pharmaceuticals launches IMCIVREE in Japan following NHI price listing
    Rhythm Pharmaceuticals commenced commercial distribution of IMCIVREE (setmelanotide) in Japan following formal Ministry of Health, Labour and Welfare (MHLW) regulatory clearance. Inclusion on Japan's National Health Insurance price list ensures national reimbursement coverage, establishing the first available therapeutic option for patients with acquired hypothalamic obesity in Japan.
    RYTM
    Impact
    60
    OCT 14
    SIG
    85%
    RYTM
    Rhythm Pharmaceuticals launches IMCIVREE in Japan following NHI price listing
    Rhythm Pharmaceuticals commenced commercial distribution of IMCIVREE (setmelanotide) in Japan following formal Ministry of Health, Labour and Welfare (MHLW) regulatory clearance. Inclusion on Japan's National Health Insurance price list ensures national reimbursement coverage, establishing the first available therapeutic option for patients with acquired hypothalamic obesity in Japan.
    → National Health Insurance reimbursement listing unlocks immediate commercial access and ex-US revenue generation in the Japanese market.
    Impact
    Rhythm Pharmaceuticals commenced commercial distribution of IMCIVREE (setmelanotide) in Japan following formal Ministry of Health, Labour and Welfare (MHLW) regulatory clearance. Inclusion on Japan's National Health Insurance price list ensures national reimbursement coverage, establishing the first available therapeutic option for patients with acquired hypothalamic obesity in Japan.
    Affected
    RYTM
    Transmission
    National Health Insurance reimbursement listing unlocks immediate commercial access and ex-US revenue generation in the Japanese market.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    RYTMcommercial revenue expansion via Japan National Health Insurance reimbursementUp1-3mCommercial launch of IMCIVREE in Japan following NHI price listing.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month